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Aim of the study: The aim of this study 
was to analyse the diagnostic accura-
cy of “18F-fluoro-ethyl-tyrosine (18F-FET) 
PET/CT tracer in multiple mye loma. 
Material and methods: The analysed 
group included: patients with newly 
diagnosed active myeloma (eight pa-
tients); in very good partial remission or 
complete remission (VGPR or CR) after 
treatment (nine patients); and with ac-
tive disease after relapse (15 patients).
Results: In patients with newly diag-
nosed myeloma, 64 lesions were found 
using CT and 83 lesions using 18F-FET. 
In six patients, the number of lesions 
using CT and 18F-FET was the same, and 
two had more lesions with the 18F-FET 
than with the CT. Patients in VGPR or 
CR had no FET-positive lesions. Four-
teen out of 15 patients with active re-
lapsed myeloma had 47 FET-positive 
lesions, CT assessment of the same 
group showed 282 lesions. In one pa-
tient with relapse soft tissue mass was 
found with 18F-FET but not with CT. 
Conclusions: 18F-FET can be a promising 
alternative to 18F-FDG PET/CT for myelo-
ma-related bone disease diagnosis. 
Key words: multiple myeloma, 18F-FET, 
18F-FDG PET/CT.
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Introduction
The majority of multiple myeloma patients develop bone lesions at some 
stage of their disease. According to the guidelines of the International Mye­
loma Working Group (IMWG), skeletal surveys have been considered the gold 
standard imaging modality for many years [1]. Unfortunately, this technique 
is insufficiently sensitive to detect early lesions or monitor treatment re­
sponses. A revision of the IMWG guidelines introduced magnetic resonance 
imaging (MRI) into routine clinical practice, but positive positron emission 
tomography (PET) alone remains insufficient to diagnose active myeloma [2]. 
In contrast to skeletal surveys and computed tomography (CT), PET com­
bined with CT (PET/CT) allows for direct, non­invasive visualisation of the 
tumour burden [3]. PET/CT using fluorine­labelled deoxyglucose (2­deoxy­ 
2­[18F]fluoro­D­glucose [18F­FDG] PET/CT) can be more effective than a skele­
tal survey in upstaging patients with suspected smouldering myeloma [4, 5]. 
On the other hand, 18F­FDG PET/CT can be equivocal and difficult to interpret 
in some patients with a new diagnosis. For this reason, the main indication 
for 18F­FDG PET/CT is currently evaluating and monitoring response to ther­
apy [6]. Fluoro­ethyl­tyrosine (18F­FET) is an amino acid tracer used in the 
diagnosis of brain tumours [7, 8]. Myeloma cell lines have the ability to trans­
port and partially metabolise 18F­FET [9]. Similarly to 11C­methionine, 18F­FET 
is not only taken up but also is incorporated into newly synthesised proteins 
[9, 10]. It can be of special interest while visualisation of plasma cell mass 
is a target. The aim of this study was to analyse the metabolism of 18F­FET 
tracer in vivo, in both the active phases of multiple myeloma and in patients 
who have responded to chemotherapy, to assess the potential utility of the 
application of 18F­FET in the clinical setting.
Material and methods
This study was conducted between 2014 and 2017. Thirty­two patients 
were included (Table 1). There were eight patients with newly diagnosed 
active myeloma, nine with previously treated disease in plateau phase 
(one in complete remission [CR] and eight in very good partial remission 
[VGPR] after first­line treatment), and 15 with active, relapsed disease. 
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Table 1. Clinical characteristic of the analysed patients
Number 
of patient
Sex Age Previous 
treatment
Disease status Bone disease assessment
Number of 
lesions on FET
SUVmax
value (range)
Number of 
lesions on CT
1 M 62 Yes VGPR 0 – 5
2 F 44 Yes Active, relapsed 4 3.4 (2.7–3.9) 42
3 M 55 Yes Active, relapsed 1 4.3 52
4 M 75 Yes Active, relapsed 8 3.1 (2.1–3.7) 48
5 F 58 Yes VGPR 0 – 0
6 F 73 Yes Active, relapsed 5 3.7 (3.5–3.9) 13
7 M 68 Yes Active, relapsed 4 6.2 (4.5–7.6) 31
8 F 60 Yes Active, relapsed 2 3.3 (2.6–4.2) 8
9 M 62 Yes Active, relapsed 1 3.0 1
10 M 64 Yes Active, relapsed 5 5.1 (2.5–8.7) 58
11 M 55 Yes Active, relapsed 3 2.4 (2.2–2.6) 5
12 F 55 Yes VGPR 0 – 2
13 M 63 Yes VGPR 0 – 61
14 F 57 Yes VGPR 0 – 1
15 M 79 Yes VGPR 0 – 34
16 M 41 No Active, not treated 3 4.4 (3.4­ 5.3) 3
17 F 73 Yes Active, relapsed 0 – 1
18 F 52 Yes Active, relapsed 2 3.3 (3.2–3.3) 3
19 F 64 No Active, not treated 2 5.7 (4.9–6.5) 2
20 F 50 Yes Active, relapsed 2 1.9 (1.8–1.9) 8
21 M 56 No Active, not treated 22 4.9 (2.6–8.2) 22
22 M 61 No Active, not treated 6 3.2 (2.6–8.2) 6
23 F 71 Yes VGPR 0 – 0
24 M 54 Yes Active, relapsed 7 2.4 (2.2–3.0) 11
25 M 64 No Active, not treated 3 3.9 (2.6–5.2) 3
26 F 79 No Active, not treated 18 3.4 (2.9–4.4) 9
27 M 75 Yes VGPR 0 – 68
28 M 43 Yes Active, relapsed 1 3.6 0
29 F 78 No Active, not treated 28 3.5 (3.1–3.7) 18
30 F 63 No Active, not treated 1 4.1 1
31 F 59 Yes Active, relapsed 1 2.90 1
32 F 52 Yes CR 0 – 1
FET – fluoro-ethyl-tyrosine, CT – computed tomography, VGPR – very good partial remission, CR – complete remission
Patients were diagnosed as follows: 14 with IgG myeloma, 
followed by 11 with light chain disease and seven with 
IgA type, 16 with κ light chain, and 16 with λ. Among treat­
ed patients the median number of previous chemotherapy 
lines was two (range one to five), and seven patients had 
autologous stem cell transplant (Table 1). Only patients 
with VGPR or CR were included in the inactive myeloma 
group assessment [11]. The clinical evaluation was based 
on the following: physical examination, bone marrow as­
pirate or trephine assessment, blood count, concentration 
of monoclonal protein and free light chains in serum and 
urine, serum levels of creatinine, calcium, albumin, and 
β­2 microglobulin. Each complete remission (disappear­
ance of monoclonal protein on immunofixation or Bence­
Jones protein on 24­hour urine collection) was histologi­
cally confirmed by trephine biopsy according to uniform 
criteria. Patients were not routinely explored by MRI un­
less surgical local procedure on the spine was considered. 
MRI tests were usually done after initiation of the treat­
ment, so they could not be compared with PET/CT results.
Whole body imaging with 18F-FET PET/CT
Patients fasted for at least four hours before the ad­
ministration of 18F­FET tracer, in order to maintain similar 
test conditions. The examinations were performed using 
Biograph mCT128 or Biograph mCT 20 scanners. All partic­
ipants underwent whole body imaging in two steps: first 
from the top of the skull to the upper third of the thigh and 
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then from the upper quarter of the thigh down to the feet. 
Patients received 350 ± 10 MBq of 18F­FET intravenously. 
The time between the injection and acquisition was 60 min­
utes. Acquisition of the trunk image was performed with the 
patient’s arms arranged alongside the body. The CT scan 
was acquired with the following parameters: Care Dose 
4D, 120 kV, and pitch 0.8 or 0.7 depending on the scanner. 
The CT scan was acquired during shallow breathing. 
The PET­scan was acquired with an acquisition time of 2.7 mi­ 
nutes per bed position. The total acquisition time was ap­
proximately 50 minutes depending on the height of the 
patient. The CT data were used for attenuation correction. 
Images were reconstructed using a commercial three­dimen­
sional iterative reconstruction algorithm called TrueX+tof 
(UltraHD­PET; 200 × 200 matrix, 3­mm intervals, three iter­
ations, 21 and 24 subsets). The standardised uptake value 
(SUV
max
) for each lesion was calculated on PET images using 
the whole­body low­dose CT as a reference. To compare the 
metabolic activity of 18F­FET in areas affected by MM with 
unaffected regions, several “background” areas of the body 
were tested: the Th10 and L4 vertebrae and the spleen, the 
brain, and the left gluteus maximus muscle. To assess the 
physiological activity in these organs SUV
max
 values were 
calculated. During the PET examination, the result was con­
sidered positive when focal myeloma infiltration, defined 
as circumscribed areas of high 18F­FET PET metabolism with 
a corresponding bone or soft tissue change, was found. 
The SUV
max
 values of the background areas were calculated 
in volume of interest (VOI) 5 cm3 ±10%. These regions were 
chosen according to observation of the whole­body PET. 
These areas were most stable and assured enough space to 
create VOIs as stated above. Each case was evaluated inde­
pendently by two experienced nuclear medicine specialists 
working independently (BM, RL), as well as by an experi­
enced radiologist.
Sensitivity was calculated as the number of lesions cor­
rectly diagnosed by FET as being positive in CT out of the 
total positive lesions in CT (S = TP/TP + FN), and expressed 
as a percentage. The positive predictive value (PPV) was 
calculated as the number of lesions correctly diagnosed by 
FET as being positive in CT out of the total positive lesions 
in FET (PPV = TP/TP + FP), and expressed as a percentage 
(PPV = TP/TP + FP). The true positive (TP) event number 
was defined as the set of lesions correctly diagnosed by 
FET as being positive in CT. The number of false positive 
(FP) events was defined as the set of lesions predicted by 
FET as being positive in CT. 
The study was performed in accordance with the prin­
ciples of the Helsinki Declaration and was based on the 
approval given by the local Bioethical Committee. Each 
participant signed an informed consent form to partici­
pate in the study.
Results
Because histological proof could not be obtained for every 
lesion, low­dose CT served as a standard of reference in 
this study. Focal lesions were found on CT in 29 of 32 pa­
tients (91%). In total, 518 lesions were found (median 6, 
range 1–68; Table 1). Foci described as positive presented 
significant enhanced 18F­FET uptake. In all patients with 
multiple lesions the metabolic activity (SUV
max
) in the 
background areas, apart from the spleen, was lower than 
the lowest SUV
max
 value in pathologically involved areas. 
The only exceptions were two patients in whom one lesion 
had a value lower than one background area, but the activ­
ity inside the lesion was clearly higher than in surrounding 
tissue. In total, 129 18F­FET­positive lesions were found in 
22 of 32 patients (69%), with a median of 3 (range: 1–28). 
The mean SUV
max
 of focal osteolytic 18F­FET­positive lesions 
was 3.45 (range: 1.9–6.2) in comparison to the mean SUV
max
 
of the background: brain 1.15 (range: 0.6–1.8; p < 0.00004), 
the mean SUV
max
 of the spleen was 2.15 (range: 1.7–3.4; 
p < 0.00008), the mean SUV
max
 of the spine at Th10 was 
1.90 (range: 1.2–3.7; p < 0.00005), the mean SUV
max
 of 
the spine at L4 was 1.80 (range: 1.1–4.9; p < 0.00005), and 
mean SUV
max
 of the gluteus muscle was 1.75 (range: 1.4–2.3; 
p < 0.00001) (Table 2). In total, 129 lesions were visible 
on 18F­FET and 518 lesions on CT. The sensitivity of the 
18F­FET/CT assessment was 55.58% (95% CI: 52.31–
58.80%), specificity was 9.09% (95% CI: 1.12–29.16%), PPV 
was 96.28% (95% CI: 95.23–98.55%), and the negative pre­
dictive value was 0.48% (95% CI: 0.13–1.78%).
From the myeloma activity point of view, three groups 
could be discriminated: those with newly diagnosed ac­
tive myeloma (eight patients); myeloma patients with 
confirmed VGPR or CR after treatment (nine patients), and 
those with active disease after relapse (15 patients). On CT 
scans, lesions were found in all patients with newly diag­
nosed disease (median 5, range: 1–22), in all but two pa­
tients from the second group (median 5, range: 1–68), and 
in 14 patients with relapsed myeloma (median 8, range: 
1–52; Figs. 1–3; Table 1). 
All but one patient with active disease (group 1 
and group 3) had 18F­FET­positive lesions (median 3, 
range: 1–28). In patients from group 1 with newly diag­
nosed mye loma, 64 lesions were found on CT and 83 on 
18F­FET. In six patients, the number of lesions on CT and 
18F­FET was the same, and two had more lesions on 18F­FET 
than on CT (Table 1). In this subgroup the sensitivity 
of 18F­FET was 100% (95% CI: 96.65–100%), specificity 
was 9.09% (1.12–29.16%), and PPV was 80.58% (95% CI: 
78–82.57%). 
Patients with CR and VGPR had no FET­positive lesions. 
One of the patients in CR, according to the assessment 
of the treating physician, had an equivocal lesion on CT, 
which was positive on standard PET with fluorine­labelled 
deoxyglucose (2­deoxy­2­[18F]fluoro­D­glucose [18F­FDG]) 
used as a tracer. Subsequent examination with 18F­FET 
tracer did not reveal any activity (Fig. 4). Obviously, the bi­
opsy of the affected area could not be performed.
From 15 patients with active relapsed myeloma (group 3), 
47 FET­positive lesions were found in 14 of them (median 3, 
range: 1–8). CT assessment of the same group showed 
282 lesions in 14 patients (median 9.5, range: 1–58). One 
of the patients had soft tissue mass (soft palate) with in­
creased FET activity and with no visible lesions on CT. 
The sensitivity of the test was 54.44% (95% CI: 50.04–
58.79%), specificity was 66.67 % (95% CI: 9.43–99.16%), 
and the PPV was 99.65% (95% CI: 98.27–99.93%).
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Table 2. SUV value of the affected area and the background in the analysed group of patients
Patients Background
Number 
of patient
Number of bone 
lesions in FET
SUVmax
value (range)
Brain Spleen Spine Th10  Spine L4 Musculus 
gluteus
1 0 – Max 1.3; 
Mean 0.9
Max 2.3; 
Mean 1.5
Max 3.1;  
Mean 1.6
Max 2.8; 
Mean 1.5
Max 1.6; 
Mean 1.1
2 4 3.4 (2.7–3.9) Max 1.2;  
Mean 0.8
Max 2.5; 
Mean 1.4
Max 2.5; 
Mean 1.5
Max 2.5; 
Mean 1.5
Max 1.6; 
Mean 1.1
3 1 4.3 Max 0.8; 
Mean 0.5
Max 2.1;  
Mean 1.2
Max 2.2; 
Mean 1.1
Max 1.7;  
Mean 1.0
Max 1.8; 
Mean 1.2
4 8 3.1 (2.1–3.7) Max 0.8; 
Mean 0.6
Max 2.1;  
Mean 1.5
Max 2.0; 
Mean 1.4
Max 1.8; 
Mean 1.1
Max 1.9; 
Mean 1.3
5 0 – Max 1.3;  
Mean 0.9
Max 2.0; 
Mean 1.3
Max 1.6; 
Mean 1.1
Max 2.0; 
Mean 1.2
Max 1.7;  
Mean 1.1
6 5 3.7 (3.5–3.9) Max 1.2;  
Mean 0.8
Max 3.0; 
Mean 2.0
Max 3.3; 
Mean 1.5
Max 2.2; 
Mean 1.4
Max 2.3; 
Mean 1.5
7 4 6.2 (4.5–7.6) Max 1.3;  
Mean 0.8
Max 3.4; 
Mean 2.2
Max 3.7; 
Mean 2.0
Max 4.9; 
Mean 2.7
Max 2.2; 
Mean 1.3
8 2 3.3 (2.6–4.2) Max 1.5;  
Mean 1.1
Max 2.1;  
Mean 1.4
Max 1.9; 
Mean 1.3
Max 1.3;  
Mean 0.7
Max 2.0; 
Mean 1.3
9 1 3.0 Max 1.1;  
Mean 0.9
Max 2.3; 
Mean 1.7
Max 2.0; 
Mean 1.3
Max 1.5;  
Mean 1.0
Max 1.7;  
Mean 1.3
10 5 5.1 (2.5–8.7) Max 1.0; 
Mean 0.9
Max 2.5; 
Mean 2.2
Max 2.2; 
Mean 1.9
Max 1.2;  
Mean 1.1
Max 2.1;  
Mean 1.8
11 3 2.4 (2.2–2.6) Max 1.5;  
Mean 1.4
Max 2.6; 
Mean 2.3
Max 1.8; 
Mean 1.7
Max 2.1;  
Mean 1.9
Max 2.0; 
Mean 1.8
12 0 – Max 0.8;
Mean 0.5
Max 2.0; 
Mean 1.4
Max 2.1;  
Mean 1.4
Max 1.4; 
Mean 0.9
Max 1.4; 
Mean 1.0
13 0 – Max 0.6; 
Mean 0.5
Max 1.9; 
Mean 1.4
Max 1.5;  
Mean 1.0
Max 1.3;  
Mean 0.8
Max 1.4; 
Mean 1.1
14 0 – Max 1.0; 
Mean 0.8
Max 2.0; 
Mean 1.8
Max 1.5;  
Mean 0.9
Max 1.5;  
Mean 1.2
Max 2.2; 
Mean 1.8
15 0 – Max 1.1;  
Mean 0.9
Max 2.5; 
Mean 1.8
Max 1.9; 
Mean 1.0
Max 2.0; 
Mean 1.4
Max 1.8; 
Mean 1.4
16 3 4.4 (3.4–5.3) Max 0.8; 
Mean 0.6
Max 2.1;  
Mean 1.5
Max 2.1;  
Mean 1.3
Max 2.1;  
Mean 1.2
Max 1.4; 
Mean 1.1
17 0 – Max 1.2;  
Mean 1.0
Max 2.2; 
Mean 1.8
Max 1.6; 
Mean 1.1
Max 1.8; 
Mean 1.4
Max 1.8; 
Mean 1.5
18 2 3.3 (3.2–3.3) Max 1.3;  
Mean 1.0
Max 2.6; 
Mean 2.1
Max 1.6; 
Mean 1.0
Max 1.8; 
Mean 1.4
Max 1.9; 
Mean 1.5
19 2 5.7 (4.9–6.5) Max 1.0; 
Mean 0.8
Max 1.8; 
Mean 1.4
Max 1.3;  
Mean 1.0
Max 1.1;  
Mean 0.8 
Max 1.5;  
Mean 1.3
20 2 1.9 (1.8–1.9) Max 1.4; 
Mean 1.2
Max 2.4; 
Mean 1.9
Max 1.6; 
Mean 1.2
Max 1.2;  
Mean 0.8
Max 1.6; 
Mean 1.3
21 22 4.9 (2.6–8.2) Max 1.2;  
Mean 1.0
Max 1.7;  
Mean 1.5
Max 2.5; 
Mean 1.7
Max 2.3; 
Mean 1.8
Max 1.5;  
Mean 1.3
22 6 3.2 (2.6–8.2) Max 1.0; 
Mean 0.7
Max 1.8; 
Mean 1.2
Max 1.7;  
Mean 1.1
Max 1.5;  
Mean 1.1
Max 1.5;  
Mean 1.2
23 0 – Max 1.4; 
Mean 1.1
Max 2.4; 
Mean 1.9
Max 1.6; 
Mean 1.1
Max 2.3; 
Mean 1.5
Max 2.0; 
Mean 1.6
24 7 2.4 (2.2–3.0) Max 1.0; 
Mean 0.8
Max 2.2; 
Mean 1.7
Max 1.7;  
Mean 1.2
Max 1.3;  
Mean 0.9
Max 1.7;  
Mean 1.5
25 3 3.9 (2.6–5.2) Max 1.0; 
Mean 0.8
Max 2.0; 
Mean 1.4
Max 1.8;  
Mean 1.2
Max 2.0; 
Mean 1.2
Max 1.7;  
Mean 1.2
26 18 3.4 (2.9–4.4) Max 1.3;  
Mean 1.0
Max 2.5; 
Mean 2.0
Max 3.3; 
Mean 2.4
Max 3.5; 
Mean 2.4
Max 2.3; 
Mean 2.0
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Discussion
Numerous studies have shown the usefulness of 18F­FDG 
PET/CT in the diagnosis of bone disease in patients with 
myeloma [12]. In a prospective study designed to compare 
18F­FDG PET­CT with whole­body X­ray (WBXR) and MRI, the 
latter was shown to be the most sensitive in the detection 
of diffuse bone marrow involvement, but PET/CT provided 
additional and valuable information for the assessment of 
myeloma bone disease in areas not covered by MRI and 
WBXR [13, 14]. In a systematic review of eight studies, in­
cluding 798 patients, and comparing 18F­FDG PET/CT with 
WBXR and MRI, a higher sensitivity of FDG PET in the detec­
tion of myeloma bone lesions was shown in six studies [15]. 
Other reviews confirmed no difference between 18F­FDG 
PET/CT and MRI in the detection of myeloma­related 
bone disease in terms of sensitivity and specificity [3, 16]. 
The IMWG updated criteria for diagnosis of multiple mye­
loma says that increased uptake on PET/CT alone is not 
adequate for diagnosis of myeloma [2]. The reason for 
this is the possibility of false positive and false negative 
results [17, 18]. There are multiple reasons for false posi­
tivity of 18F­FDG PET, including: inflammation or infection, 
bone remodelling, recent chemotherapy or radiotherapy, 
or growth factor support; and for false negativity: hyper­
Patients Background
Number 
of patient
Number of bone 
lesions in FET
SUVmax
value (range)
Brain Spleen Spine Th10  Spine L4 Musculus 
gluteus
27 0 – Max 0.9;
Mean 0.6
Max 2.1;  
Mean 1.8
Max 2.2  
Mean 1.2
Max 1.2;  
Mean 0.8
Max 1.8; 
Mean 1.4
28 1 3.6 Max 1.0; 
Mean 0.8 
Max 2.0; 
Mean 1.6
Max 1.5;  
Mean 1.0
Max 1.6; 
Mean 1.2
Max 1.7;  
Mean 1.5
29 28 3.5 (3.1–3.7) Max 1.1;  
Mean 0.8
Max 2.7; 
Mean 2.2
Max 3.7; 
Mean 2.5
Max 3.3; 
Mean 2.6
Max 1.6; 
Mean 1.3
30 1 4.1 Max 1.2;  
Mean 1.2
Max 2.5; 
Mean 2.4
Max 2.5; 
Mean 2.2
Max 2.3; 
Mean 2.0
Max 1.9; 
Mean 1.7
31 1 2.90 Max 1.1;  
Mean 0.9
Max 2.0; 
Mean 1.7
Max 1.2;  
Mean 0.6
Max 1.5;  
Mean 1.2
Max 1.8; 
Mean 1.5
32 0 – Max 1.2;
Mean 0.9
Max 2.4;
Mean 1.7
Max 1.6;
Mean 1.3
Max 1.8;
Mean 1.3
Max 1.8;
Mean 1.4
Table 2. Cont. 
Fig. 1. Patient no. 12, newly diagnosed multiple myeloma before the treatment. A) Computed tomography – lytic lesion localised in the 
sternum. B) The same lesion on 18F-FET PET/CT fusion image with high FET uptake (converted to black and white). C) Computed tomography 
– lytic lesion localised in the right iliac crest. D) 18F-FET PET/CT fusion image with high FET uptake in iliac crest 
A B
C D
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Fig. 2. The same patient after completion of therapy. A) Computed tomography (CT) – lytic lesions localised in the sternum – no difference 
to the status before therapy. B) 18F-FET PET/CT, fusion image with low FET uptake in the lytic lesion visible on CT in sternum. C) Computed 
tomography – lytic lesion localised in the right iliac crest – no difference to the status before therapy. D) 18F-FET PET/CT fusion image with 
low FET uptake in iliac crest 
A B
C D
Fig. 3. Patient no. 21. Myeloma-related lesions before and after the treatment. MIP images of the FET uptake in the patient body. A) Multiple 
FET lesions localised in the skeleton of the pathological uptake of FET. B) MIP image after chemotherapy. Complete disappearance of patho-
logical FET uptake may suggest metabolic response to the treatment
A B
glycaemia, recent administration of high­dose steroids, or 
the presence of sub­centimetre lytic lesions close to the 
brain [6]. As yet, no consensus has been reached regarding 
an appropriate SUV
max
 cut­off value to distinguish positive 
and negative readings [19]. 
In order to individualise and improve patients’ manage­
ment there is an obvious need to develop a novel tracer. 
In an attempt to find such a tracer some research groups 
focused on a characteristic feature of plasma cells – ex­
cessive production of immunoglobulin particles and used 
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amino acid labelled with radioisotopes, such as methio­
nine labelled with carbon (11C­MET) or a fluorine­labelled 
fluoro­ethyl­tyrosine (18F­FET) instead of FDG. One of them 
is 11C­MET, which is used in the diagnosis of a wide range 
of cancers. In preliminary myeloma studies it was found 
that the uptake of 11C­MET exceeds that of 18F­FDG by 
1.5­ to 5­fold [9, 20]. 
Luckerath et al. evaluated the radiotracers 11C­MET 
and 18F­FDG, on myeloma cells, to monitor the response 
to anti­myeloma­therapy, and for outcome prediction [10]. 
11C­MET­uptake, but not 18F­FDG, significantly decreased 
after a bortezomib injection to myeloma cell lines. Early 
reduction of 11C­MET correlated with improved survival in 
mice. 
Usefulness of 11C­MET in a clinical scenario was de­
scribed by Nakamoto et al., who compared 11C­MET and 
18F­FDG in vivo using this tracer to analyse 20 patients (six 
patients with active myeloma and 14 after the treatment) 
[21]. All the results were compared between the two scans. 
11C­MET uptake tended to be higher and more lesions 
of grade 3 or 4 were depicted by 11C­MET than by 18F­FDG 
PET/CT. The patient­based sensitivity, specificity, and accu­
racy of 11C­MET for restaging were 89%, 100%, and 93%, re­
spectively, while those of FDG were 78%, 100%, and 86%, 
respectively [21]. 
Recent results were published by Lapa et al., who pre­
sented 43 patients with myeloma, who underwent both 
MET­ and FDG­PET/CT for staging or re­staging [22]. Eleven 
of them had a new disease, and 32 had been pre­treated 
with various numbers of chemotherapy regimens. Scans 
were compared regarding patients and lesions. Both trac­
ers correlated with a degree of plasma cell bone marrow 
involvement and clinical parameters reflecting disease ac­
tivity with 11C­MET demonstrating a stronger correlation. 
11C­MET was also superior in staging and re­staging intra­ 
and extramedullary bone lesions. 
Okasaki et al. compared 11C­MET with 18F­FDG and 
11C­4’thithymidine (11C­4DST) in 64 patients. Traditional CT 
was able to find 55 focal lytic lesions in 24 patients. Both 
11C­MET and 11C­4DST were equally effective in mye loma­
related lesions, and both were more sensitive than 18F­FDG. 
Unfortunately, 11C­MET can be used only in centres that are 
equipped with cyclotron and have the possibility of 11C pro­
duction. 
Another tracer investigated in patients with multiple 
myeloma by Nanni et al. was 11C­Choline. Ten of the pa­
tients underwent standard 11C­Choline PET/CT and 18F­FDG 
PET/CT. 11C­Choline PET/CT was capable of finding more 
lesions and showed a higher mean SUV
max
 than 18F­FDG. 
Other tracers investigated by various groups were: 3’­fluoro­ 
3’­deoxy­L­thymidine (18F­FLT), 18F­Sodium Fluoride (18F­NaF), 
or 18F­fluorocholine (FCH) [23–26]. All of them required fur­
ther investigations. 
In contrast to the above, very little is known about 
18F­FET in the setting of multiple myeloma bone disease. 
For 18F­FET PET/CT cyclotron on­site is not necessary; it can 
be implemented in every centre using PET/CT, but the data 
from cell lines suggests that the relative uptake of ¹¹C­MET 
exceeds that of 18F­FET 7 to 20­fold [9]. In our study, we 
tried to assess the sensitivity and positive predictive value 
Fig. 4. Patient no. 32. A) Solitary myeloma lesion suspected in the right palatine tonsil, positive in FDG PET/CT, showing high uptake SUVmax 18.77. 
B) Negative FET PET/CT result showing no tracer uptake in the right tonsil. No subsequent clinical progression of myeloma was observed 
on further follow-up
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of functional imaging modalities 18F­FET in detecting mye­
loma­related lesions using CT as a standard of reference.
A mismatch between PET/CT with 18F­FDG as a tracer 
and anatomic imaging modalities, regarding demonstra­
tion of myeloma lesions, was described by Caers et al. [3]. 
It confirmed that standard low­dose CT is not capable of 
discriminating between vital and fibrotic myeloma­related 
lesions [27]. 
Focal lesions may remain positive on CT or hyper­ 
intense on MRI for several months after treatment, in re­
sponding or non­responding patients, because of treat­
ment­induced necrosis or inflammation [28], which could 
be an explanation for the difference between the number 
of lesions observed in CT and in FET in patients previous­
ly treated and being in plateau or with recurrence of the 
disease in our patients. On the other hand, in untreated 
patients from our cohort the number of observed lesions 
on 18F­FET PET/CT was higher than on standard CT, which 
might suggest a possible increased sensitivity of our tracer 
in the detection of active disease. Our hypothesis is that 
high 18F­FET uptake reflects activity of the plasma cell pro­
duction. 
Association between intracellular Ig light chains with 
MET uptake was already reported by Luckerath et al. [9]. 
The presence of myeloma­related bone disease, reflected 
by positive lesions on CT, is a secondary event. It can ex­
plain why 18F­FET­positive lesions were found in areas neg­
ative on CT in patients with primary or secondary active 
disease but not in patients in CR or VGPR.
We hope that 18F­FET tracer will be able to overcome 
the weaknesses of PET/CT based on 18F­FDG. A lack of ac­
tivity in the patient with complete remission can suggest 
better specificity of 18F­FET than standard 18F­FDG PET/CT. 
It is possible that 18F­FET PET/CT is capable of patients 
with active disease, which we saw in the group of patients 
with newly diagnosed myeloma. Because of the small co­
hort of patients in our study the presented results require 
further validation.
The authors declare no conflict of interest.
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